Apollomics reports full year 2024 financial results and highlights clinical updates and business progress

Foster city, calif., april 03, 2025 (globe newswire) -- apollomics inc. (nasdaq: aplm) (“apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended december 31, 2024, and highlighted clinical updates and business progress.
APLM Ratings Summary
APLM Quant Ranking